Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis

The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response. The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.

NCT Number	NCT07674134
Lead Sponsor	Centre Hospitalier Princesse Grace
Conditions	Rheumatoid Arthritis (RA)
Enrollment	90 participants
Start Date	2024-04-23
Primary Completion	2026-11 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2026-06-29